



- 24  $\frac{4}{10}$  Department of Orthodontics, & The Iowa Institute for Oral Health Research, College of
- 25 Dentistry, University of Iowa, Iowa City, IA, USA
- <sup>26</sup> <sup>5</sup> Department of Health Management and Policy, College of Public Health, University of Iowa,
- 27 Iowa City, IA, USA
- 28 <sup>6</sup> Fundación Clínica Noel; Calle 14 # 43B 146, Medellín, Antioquia, Colombia
- 29 <sup>7</sup> Department of Pediatrics, College of Medicine, Institute of Human Genetics, National
- 30 Institutes of Health, University of the Philippines, Manila, the Philippines
- 31 <sup>8</sup> UCHealth Medical Group, Colorado Springs, CO. USA
- <sup>9</sup> Unit of Epidemiology, Department of Public Health, University of Southern Denmark, Odense,
- 33 Denmark
- $34$   $10$  CEMIC-CONICET: Center for Medical Education and Clinical Research, Buenos Aires,
- 35 Argentina.
- 36 <sup>11</sup> Department of Genetics, Institute of Biology, Federal University of Rio de Janeiro, Rio de
- 37 Janeiro, Brazil
- 38 <sup>12</sup> Instituto Nacional de Genética Médica Populacional INAGEMP, Porto Alegre, Brazil.
- <sup>13</sup> Department of Pediatrics, University of Texas Health Science Center at Houston, Houston,
- 40 TX, USA
- <sup>14</sup> Dental and Craniofacial Genomics Core, School of Dental Medicine, University of Puerto
- 42 Rico, San Juan, Puerto Rico
- <sup>15</sup> Department of Oral Pathology, Radiology and Medicine and Iowa Institute for Oral Health
- 44 Research, College of Dentistry, University of Iowa, Iowa City, IA, USA

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- <sup>16</sup> Department of Oral and Maxillofacial Surgery, College of Medicine, University of Lagos,
- 46 Lagos, Nigeria.
- <sup>17</sup> Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA,
- 48 USA
- 49 <sup>18</sup> Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA
- 50 <sup>19</sup> Clinical and Translational Science, School of Medicine, University of Pittsburgh, Pittsburgh,
- 51 PA, USA
- 52 \*\* co-senior-authors

## 53 **ABSTRACT**

54 Orofacial clefts (OFCs) are among the most common craniofacial birth defects and constitute 55 a high public health burden around the world. OFCs are phenotypically heterogeneous, affecting 56 only the lip, only the palate, or involving both the lip and palate. Cleft palate alone is 57 demonstrably a genetically distinct abnormality from OFCs that involve the lip, therefore, it is 58 common to study cleft lip (CL) in combination with cleft lip plus cleft palate (CLP) as a 59 phenotypic group (i.e. cleft lip with or without cleft palate, CL/P), usually considering CLP to be 60 a clinically more severe form of CL. However, even within CL/P, important genetic differences 61 among subtypes may be present. The Pittsburgh Orofacial Cleft (Pitt-OFC) multiethnic study is a 62 rich resource for the study of non-syndromic OFC, comprising a large number of families 63 (~12,000 individuals) from multiple populations worldwide: US and Europe (whites), Central 64 and South America (mixed Native American, European and African), Asia, and Africa. In this 65 study we focused on the CL/P families from this resource grouped into three non-overlapping 66 family types: those with only CL affected members, only CLP affected members, or both CL and 67 CLP. In all, seven total subtypes besides the combined CL/P phenotype, were defined based on

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



81

## 82 **AUTHOR SUMMARY**

83 Orofacial clefts are common birth defects. Clefts often run in families, but their genetic basis 84 is still an active area of investigation. In this study, we use an innovative approach to identify 85 shared and unique genetic risk factors between two types of orofacial clefts - cleft lip and cleft 86 lip plus cleft palate, by taking the patterns of different cleft types reported in families into 87 account. Our study provides new insights into previously known genetic risk factors, but also 88 identifies novel genetic regions that differentially impact the risk of developing cleft lip versus 89 cleft lip plus cleft palate. This study contributes to the growing evidence that different sets of

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

90 genes impact different forms of clefting and highlights the importance of incorporating

91 information about familial affection patterns into analyses.

92

## 93 **INTRODUCTION**

94 Orofacial clefts (OFCs) are among the most common birth defects worldwide. The physical 95 health effects of OFCs pose social, emotional and financial burdens on affected individuals and 96 their families [1-3], despite therapies such as surgical treatments, ongoing orthodontia, speech 97 therapy etc. that are available to reduce these burdens. Similar to other birth-related 98 malformations, there are disparities in access to the complex medical and surgical therapies for 99 OFCs[4]. A variety of studies have reported a reduced quality of life for children with OFC [5], 100 as well as a higher risk of certain types of cancers in adulthood [6-8]. Thus, identifying etiologic 101 factors responsible for OFCs is a very important tool for determining risk, designing prevention 102 methods, and determining the extent of therapeutic and social support needed by individuals with 103 OFCs and their families. 104 OFCs are heterogeneous with varying manifestations and severity but are typically 105 categorized into three subtypes: cleft lip alone (CL), cleft palate alone (CP), and cleft lip plus 106 cleft palate (CLP). These can be syndromic (i.e. part of a spectrum of multiple defects due to a 107 single cause), but the majority, about 70% of CL with or without CP (CL/P) and 50% of CP, are 108 non-syndromic (i.e. the only defect present without any other detectable cognitive or structural 109 abnormality) [9]. Many of the genes responsible for Mendelian forms of syndromic OFCs have 110 been identified (OMIM, https://www.omim.org/search/advanced/geneMap) as have some

111 teratogenic causes (ref?). In contrast, our understanding of the genetic causes of non-syndromic

112 OFCs (nsOFCs) remains incomplete due to the complex nature of these defects, despite studies

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

113 over a number of years [10, 11]. Not only are there differences in birth prevalence around the 114 world with respect to any nsOFC, the prevalence of the various subtypes (CL, CLP, CP) also 115 varies substantially, suggesting etiological differences in the genetic factors giving rise to these 116 different forms of nsOFC. These differences likely reflect the fact that human craniofacial 117 development is a multi-stage process involving complex interactions between genetic and 118 environmental factors [11].

119 Historically, CL and CLP have been treated as variants of the same defect based on 120 embryological origins of the upper lip and secondary palate, with CLP being considered a more 121 severe form of CL [14]. Analysis of recurrence risk among siblings have shown that the cross-122 subtype recurrence risk ratio between CL and CLP is higher than between CP and either CL or 123 CLP [15], and analyzing the composite phenotype with lip involvement (CL/P) within 124 association analyses have resulted in consistently stronger signals, than analyzing all three (CL, 125 CLP, CP) as a combined phenotype. Therefore, CP has been treated as being genetically distinct 126 from nsOFCs involving the lip. More recently, it has been shown that CL and CLP have shared 127 and unique etiological factors, therefore, recent genetic studies have focused on investigating 128 etiological differences between CL and CLP, including both candidate gene approaches [16, 17] 129 as well as genome-wide association study (GWAS) approaches [18-20]. 130 Our current study focuses on nsOFC and investigates whether CL is etiologically different 131 from CLP by considering the types of clefts segregating within families. This family-type based 132 approach was previously used for genome-wide linkage-analyses [21], but has not been

133 employed for GWASs. Following a methodology similar to the prior family-based analysis for

134 partitioning families [21], we created several GWAS samples and phenotypes, as defined in the

135 Terminology section below, and described in detail in Methods. This approach stands in contrast



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



- 160 members excluded), or only CLP members set to affected (CL members excluded) respectively.
- 161 Finally,  $CL_{[CL+]}$  and  $CLP_{[CLP+]}$  are samples consisting of the  $CL+$  or  $CLP+$  family groups;
- 162 respectively, but with only CL members set to affected (CLP members excluded), or only CLP
- 163 members set to affected (CL members excluded). Fig 1 shows the GWAS sample definition and
- 164 phenotype assignment used in this study. Table 1 lists selected prior studies of OFC types on
- 165 Pitt-OFC subjects that most closely resemble the subset and phenotypes analyzed in our study.





167

168 Since the degree of OFC risk at certain susceptibility loci varies with ancestry [22], the effect 169 of ancestry was incorporated into our analyses. The four ancestry groups used to classify study 170 participants are AFR (African ancestry), ASIA (Asian ancestry), EUR (white, European 171 ancestry) and CSA (Central and South American ancestry). EAF is used to denote the effect

- 172 allele frequency within a specified subset of participants. LD  $r^2$  is used to denote linkage
- 173 disequilibrium between variants as observed within the POFC sample.
- 174
- 175 Fig 1. Creation of analytical subsets and phenotype assignment for GWAS.
- 176 Fig 1 caption. Each colored rectangle is a GWAS phenotypic subset; included pedigree type(s)
- 177 shown for each subset; shaded squares and circles indicate participants with an OFC; shaded
- 178 circles and squares with solid outlines indicate **affected** subjects; unshaded squares and circles
- 179 with solid outlines represent **unaffected** subjects; circles and squares with dotted outlines
- 180 represent pedigree members **excluded** from the GWAS; designations for OFC phenotype
- 181 analysis subgroups including a subscript for the family type(s) are:
- 182 (A) **CL/P[POFC]:** full set of [CL], [CLP] and [CL+CLP] pedigrees, CL and CLP members set 183 to affected;
- 184 (B)  $CL<sub>[CL]</sub>$ : in [CL] pedigrees, CL members are set to affected;
- 185 (C) **CLP[CLP]**, in [CLP] pedigrees CLP members are set to affected;
- 186 (D) **CL/P[CL+CLP]**, in [CL+CLP] pedigrees, CL and CLP members are set to affected;
- 187 (E) **CL[CL+CLP]**, in [CL+CLP] pedigrees, CL members set to affected, CLP members 188 excluded;
- 189 (F) **CLP**[CL+CLP], in [CL+CLP] pedigrees, CLP members are set to affected and CL members 190 excluded;
- 191 (G) **CL[CL+]**, in [CL+] pedigrees (i.e. [CL] plus [CL+CLP] pedigrees), CL members are set to 192 affected and CLP members excluded;
- 193 (H) **CLP[CLP+]**, in [CLP+] pedigrees (i.e. [CLP] plus [CL+CLP] pedigrees), CLP members 194 are set to affected and CL members excluded.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

195 Note: Affected sibships are shown as examples – data includes other pedigree types including 196 multi-generational pedigrees.

## 197 **RESULTS**

198 In our study, GWASs of eight separate phenotypes were run on eight corresponding 199 phenotypic subsets created by grouping the POFC pedigrees based on the type of OFCs (CL 200 and/or CLP) observed within those pedigrees. The full sample was analyzed for the CL/P 201 phenotype (CL/P<sub>[POFC]</sub>), and seven other phenotype/family groups,  $CL_{[CL]}$ ,  $CLP_{[CLP]}$ , 202 CL/P<sub>ICL+CLP</sub>, CL<sub>ICL+CLP</sub>, CLP<sub>ICL+CLP</sub>, CL<sub>ICL+1</sub> and CLP<sub>ICLP+1</sub> were defined, and analyzed using 203 GWASs. For each phenotype, pedigrees were further grouped according to their population 204 ancestry groups, and GWASs run separately within each group. Subsequently, association 205 outcomes for the ancestry groups were meta-analyzed to determine association for each of the 206 eight phenotypic subsets. The procedure followed for creating and analyzing the eight 207 phenotypic subgroups is described in the Methods section. Genome-wide meta-analysis resulted 208 in several significant and suggestive associations, both at previously reported OFC loci, and five 209 novel regions.

210

## 211 **Significant and suggestive loci identified by meta-analysis**

212 Meta-analysis over the ancestry groups for each of the eight phenotypes resulted in fourteen 213 unique loci of interest. These included five novel loci with genome-wide Bonferroni significant 214 meta-analysis p-values ( $p < 5.0e-08$ ) and an additional nine known OFC loci with p-values 215 below 1.0E-06. Table 2 lists the most significant meta-analysis p-value, effect size (expressed as 216 betas), 95% CI of the effect size, and the variant positions that showed significant ( $p < 5.0e-08$ ) 217 or suggestive (p < 1.0e-05) associations. Supplementary Table S1 provides more detailed



- 219 numbers, base pair positions, and effect allele frequencies (EAFs) within the affected subjects
- 220 included for GWAS of that phenotype.
- 221 The five novel associations observed are: (i) 3q29, most significantly associated with the
- 222 CL<sub>[CL+CLP]</sub> subtype, (ii) 5q13.2, most significantly associated with the CL<sub>[CL+]</sub> subtype, (iii)
- 223 7q22.1 showing the strongest association with the CLP  $_{\text{ICL+CLPI}}$  subtype, (iv) 19p13.3 also
- 224 showing the strongest association with the  $CLP_{[CL+CLP]}$  subtype, and (v) 20q13.3, associated with 225 the  $CL_{[CL]}$  subtype.
- 226 The known OFC loci recapitulated here include the genes *PAX7, IRF6, FAM49A, DCAF4L2,*
- 227 *ARID3B, NTN1, WNT9B:WNT3, TANC2*, and the 8q24.21 locus. Among these, *PAX7, FAM49A*,
- 228 *DCAF4L2*, *ARID3B*, and *WNT9B:WNT3* are associated with both CL and CLP. The *IRF6* locus
- 229 is the most strongly associated with the  $CL_{[POFC]}$  subtype, *TANC2* with the  $CL_{[CL]}$  subtype, and
- 230 *NTN1* with CLP<sub>ICLPI</sub> subtype. The 8q24.21 locus has traditionally been treated as a single locus,
- 231 however, the prior CL/P GWAS study using samples from Pitt-OFC reported two distinct peak
- 232 regions with genome-wide significant association p-values (Leslie et al. [12]). In the current
- 233 study, we also observed two distinct peak regions at this locus. Both peaks are most strongly
- 234 associated with the  $CL/P_{[POFC]}$  subtype.





236 Note: For each locus and GWAS, meta-analysis p-value, beta estimate and its 95% CI are shown; RS numbers and their effect alleles

237 (in parentheses) are shown for suggestive and significant associations - SNPs with the most significant p values at a locus may differ

- 238 across the GWASs,; <sup>†</sup>novel loci; p-values  $\leq$  5.0E-08 highlighted in dark green and p-values  $\leq$
- 239 1.0E-06 in light green; smallest p-value across subtypes highlighted in bold; two distinct
- 240 association peaks in 8q24.21 locus listed separately.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### 241 **Identification of loci associated with specific cleft and/or family subtypes**

242 Based on the strength of association and location of the most significant variants across 243 subtypes, six previously reported OFC loci, *PAX7*, *FAM49A*, *DCAF4L2*, the 8q24.21 locus, 244 *ARID3B*, *WNT9B:WNT3* and a novel locus 7q22.1 appear to be associated with both CL and 245 CLP, i.e., the CL/P<sub>[POFC]</sub> meta p-values were the most significant at these loci with subtypes 246 represented by the larger samples -  $CLP_{ICLP+1}$  and  $CLP_{ICLP1}$  - produced more significant 247 association p-values as compared to the subtypes with smaller samples. The remaining nine loci 248 produced more significant p-values within a cleft or a family subtype. We hypothesized that the 249 differences in p-values could be the result of the sample size differences between phenotypic 250 subtypes. We therefore compared the estimated meta-analysis effect sizes of the associated 251 variants within each of 15 peak regions identified above obtained for the eight phenotypes. This 252 was done to verify whether the degree of risk for developing an OFC differed by OFC type 253 and/or family type.

254 Table 2 lists the estimated beta coefficients and 95% confidence intervals for the top 255 associated variant at each locus and for each subtype GWAS. The comparison showed 256 statistically significant differences between the meta-analysis beta coefficients between subtypes 257 at five of the associated loci, both between cleft subtypes (i.e.  $CL[<sub>CI+1</sub> vs. CLP<sub>ICLP+1</sub>)]$ ) and 258 between family subtypes (i.e.  $CL_{[CL]}$ ,  $CL_{[CL]}$ ,  $CL_{[CL+CL]}$  and  $CL_{[CL+CL]}$ ). A comparison of the 259 ancestry-specific beta coefficients also showed variation similar to the meta-analysis effect sizes. 260 A comparison of the frequency of the effect allele within affected individuals included in the 261 phenotypic subsets showed that subtype-specific variants occurred at varying frequencies 262 between subgroups. Overall, case allele frequencies were observed to differ between subtypes if 263 effect sizes varied between subtypes, and vice versa.



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

286 differ from one another, if the effect sizes are different, with a single exception – the 5q13.2 287 locus, which is further explored in the next section.

## 288 *1. Loci specific to the CL cleft-subtype*

289 The novel locus at **5q13.2**, and the known **1q32.2 (***IRF6***)** locus show the most significant 290 association for the CL[POFC] cleft subtype. Fig 2 shows the *IRF6* locus in detail: the regional 291 Manhattan plot (Fig 1a) shows six distinct variants (labelled A-F) with the most significant p-292 values from the subtype meta-analyses. The top association for  $CL_{[CL+]}$  coincides with the top 293 CL<sub>ICL+CLP</sub> variant (SNP D: rs67652997 in Fig 2c), although the latter shows lower significance, 294 and the top associations for  $CLP_{ICLP+1}$  and  $CLP_{ICLP}$  also coincide (SNP B: rs2076149). LD 295 between variants with significance p-values (below 0.001) is shown for the 209.92-209.98 KB 296 region spanning five of these variants  $(A-E)$ ; the top  $CL<sub>[CL]</sub>$  association is not shown - it is in low 297 LD with the rest of the top associations.

298 The largest CL effect size is observed for the  $CL_{[CL+]}$  subtype, as can be seen in Fig 2c for 299 *IRF6*. The  $CL_{[CL+]}$  subtype's effect sizes at the lead SNP rs609659, as well as nearby variants in 300 LD with the lead SNP is distinctly larger in magnitude than for the  $CLP_{[CI,P+]}$  subtype. Effect 301 sizes for the  $CL_{[CL]}$  and  $CL_{[CL+CLP]}$  family-based subtypes are also larger than the  $CLP_{[CLP]}$  and 302 CLP<sub>[CL+CLP]</sub> effect sizes, while  $CL_{[CL]}$  and  $CL_{[CL]+CLP]}$  effect sizes are not statistically different. 303 These loci show stronger association to CL, attributable to both the  $CL_{[CL]}$  and  $CL_{[CL+CLP]}$  family 304 subtypes. Within the *IRF6* gene, the lead variant is observed to have a protective effect on CL 305 risk and observed at a lower frequency than the non-effect allele within cases in EUR and CSA. 306 Within ASIA and AFR, effect sizes appear to be similar between  $CL_{[CL+]}$  and  $CLP_{[CLP+]}$ . At the 307 5q13.2 locus, the ancestry subgroup-specific effect sizes are consistent with the meta-analysis 308 effect sizes within the ASIA, EUR and CSA subgroups, i.e.  $CL_{[CL+]}$  effect sizes are larger in

It is made available under a CC-BY-NC-ND 4.0 International license.



## 323 *2. Loci specific to the CL[CL] family-subtype*

324 At two peak regions, the novel locus at  $20q13.33$ , and  $17q23.2;q23.3$  (*TANC2*), the CL<sub>[CL]</sub>  $325$  meta-analysis p-value is the most significant, and the  $CL_{[CL]}$  meta-analysis effect sizes are much 326 larger than the other family-type based subsets. Notably, the  $CL_{[CL+]}$  effect size is not different 327 from the CLP<sub>[CLP+1</sub> subtype. Fig 3 highlights the main association outcomes at the 20q13.33 328 locus. As seen in Fig 3d, the variation in beta estimates within the CSA and EUR subgroups 329 correspond to the variation observed within the overall meta-analysis beta estimates, and the lead 330 variant for  $CL<sub>[CL]</sub>$  shows a positive effect size (beta), while other effect sizes are close to zero. 331 The effect allele was not observed in  $CL<sub>[CL]</sub>$  families from ASIA, and AFR was excluded from

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



- 333 subtype *TANC2*, effect size differences were observed in the EUR and CSA group, with
- 334 differences observed in the ASIA group. Further, within the CSA group, the  $CL_{[CL]}$  subtype
- 335 showed a positive effect whereas the  $CL_{[CL+CLP]}$  subtype showed a negative effect, which was not
- 336 the case for EUR. EAFs within the affecteds were consistently highest in the  $CL<sub>[CL]</sub>$  subtype
- 337 sample than the other family-subtypes, and the effect allele is least frequent in ASIA
- 338 (Supplement Fig S2).
- 339 Fig 3. 20q13.3 novel locus specific to  $CL<sub>[CI]</sub>$  subtype

340 Fig 3 Caption. (a) regional Manhattan plot consisting of five distinct variants (A-E) with the

341 most significant p-value from each subtype; (b) LD  $r^2$  values  $> 0.2$  between variants (A-E) with

342 p-value below 0.001; (c) beta coefficient and 95% CI for variants A-E, D: lead variant at this

343 locus, \*\* significant associations; (d) effect sizes and (e) effect allele frequency within affected

344 subjects for family subtypes  $CL_{[CL]}$ ,  $CL_{[CL+CLP]}$ ,  $CLP_{[CLP]}$  and  $CLP_{[CL+CLP]}$  by ancestry-subgroup.

345

## 346 *3. 3q29 locus specific to CL[CL+CLP] family-subtype*

347 The **3q29 novel locus** is more strongly associated with the CL[CL+CLP] subtype than any other 348 subtype (Fig 4). There is low LD between SNPs associated with different subtypes as seen in Fig 349 4b. The  $CL_{[CL+CLP]}$  subtype's effect size is much larger than that of other subtypes also resulting 350 in a significant difference between the  $CL_{[C1]+1}$  subtype's effect size and the  $CLP_{[C1]+1}$  subset's 351 effect size (Fig 4c and 4d). The **3q29** locus is another instance where ancestry plays a role. The 352 elevated beta in  $CL_{[C1]+[C1]}$  is due to samples of EUR ancestry, and the corresponding EAF in the 353 EUR subgroup is also much higher than EAFs of other family subtypes (Fig 4e). Effect size 354 variation is not observed in CSA, which is consistent with similar case EAFs in CSA, and the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 355 effect allele is very rarely observed in ASIA. When effect sizes from the ancestry-based
- 356 subgroups are examined, the difference between  $CL_{[CL]}$  and  $CL_{[CL+CLP]}$  effect sizes is observed in
- 357 the EUR subgroup, but not in ASIA and CSA.
- 358 Fig 4. 3q29 novel locus specific to  $CL_{[CL+CLP]}$  subtype
- 359 Fig 4 caption (a) regional Manhattan plot consisting of six distinct variants (A-F) with the most
- 360 significant p-value from each subtype; (b) LD  $r^2$  values  $> 0.2$  between variants (A-F) with p-
- 361 value below 0.001; (c) beta coefficient and 95% CI for variants A-F, E: lead variant at this locus,
- 362 \*\* significant associations; (d) effect sizes, and (e) effect allele frequency within affected
- 363 subjects for family subtypes  $CL_{[CL]}$ ,  $CL_{[CL+CLP]}$ ,  $CL_{[CLP]}$  and  $CL_{[CL+CLP]}$  by ancestry-subgroup.
- 364

## 365 *4. Locus specific to CLP[CL+CLP] family-subtype*

366 The **19p13.3 peak** includes a single Bonferroni-significant association at SNP rs628271;

367 with no other neighboring variants reaching a suggestive level of significance, this may not be a

368 reliable association. Even so, interestingly the effect size of this variant for the  $CLP_{[CL+CLP]}$ 

369 subtype is larger than all the other family-based subtypes. The  $CL_{[C1]+1}$  subtype effect size is

 $370$  similar to the CLP<sub>[CLP+1</sub>] effect size. This difference is observed in CSA and EUR, but not in

371 ASIA.

372

## 373 *5. Loci with no variation in subtype-specific effect sizes:*

374 At the following loci, the subtype-specific effect sizes are similar in magnitude and direction 375 to those from the other subtypes, indicating that that these loci affect the risk of both CL and 376 CLP to a similar extent regardless of family classification: 1p36.13 (*PAX7*), 2p24.2-24.3 377 (*FAM49A*), 7q22.1 - novel locus, 8q21.3 (*DC4FL2*), both peaks within 8q24.1, 15q24.1;q24.2

378 (*ARID3B*), 17p13.1 (*NTN1*), and 17q21.31;q21.32 (*WNT9B;WNT3*). At these loci, larger samples 379 yielded more significant association p-values.

## 380 **DISCUSSION**

381 For the five novel loci observed in our study, a bioinformatics search yielded interesting, but 382 not conclusive indication of their roles in the development of OFCs. The lead variant within 383 5q13.2 is in close proximity to the *TMEM1* gene, and the lead variant within the 20q13.33 locus 384 is intronic to the *CDH4* gene; both *TMEM1* and *CDH4* are involved in the Wnt signaling 385 pathway, known to be involved in the development of OFCs. The lead variant in our 3q29 locus 386 is located approximately 1 MB downstream of the *DLG1* gene, reported as being associated with 387 CL/P in a recent study of CL/P on a Polish population [23]. In our study, however, we observed 388 only weak association to variants within the *DLG1* gene. The other three loci contain craniofacial 389 super-enhancer regions. The top associations in the 7q22.1 locus are intronic to the *COL26A1*  390 and *RANBP3* genes, both reported as having a blood phenotype (UCSC genome browser, 391 https://genome.ucsc.edu/index.html). It is interesting to note that the previously reported 392 genome-wide linkage and targeted region study of Pitt-OFC pedigree subsets based on cleft 393 types [21] reported two regions – 9q21.33 and 14q21.3 – that were associated at a suggestive 394 level of significance in our study, although the current associations do not lie within the fine-395 mapped regions analyzed in the former study. 396 The analysis of CL and CLP as a single phenotype (CL/P) in the [CL+CLP] families did not 397 produce unique associations, as would be expected if these families were segregating for genes

398 that cause a continuum of the CL/P phenotype. This lack of association may further support the

399 hypothesis that CL/P is not a single phenotype etiologically. Further, we hypothesize that our

400 family subtype-based analyses show evidence of genetic heterogeneity even within the cleft



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### 421 **METHODS**

### 422 **Study sample**

423 Our study sample consists of participants from the multiethnic Pittsburgh Orofacial Cleft 424 study (Pitt-OFC) [12], including a variety of pedigree structures and sizes, and including both 425 simplex as well as multiplex families. Sample recruitment was carried out in accordance with 426 ethics approval procedures at the University of Pittsburgh, the coordinating center for the Pitt-427 OFC study, as well as the respective institutions that contributed samples to the Pitt-OFC study. 428 Genotyping was carried out at the Center for Inherited Disease Research (CIDR) at Johns 429 Hopkins University, on an Illumina chip for approximately 580,000 variants genome-wide as 430 summarized previously [12, 13], and available from dbGaP (**dbGaP Study**  431 **Accession:** phs000774.v2.p1). The CIDR coordinating center at the University of Washington 432 was also responsible for ensuring the quality of called genotypes. Subsequently, genotypes were 433 imputed using the "1000 genome project phase 3" reference panel, at approximately 35,000,000 434 variants of the GrCH37 genome assembly. Genotyping, quality control, and imputation steps 435 were previously described in detail in Leslie et al. [12]. 436 The full sample – POFC – utilized in our current study includes 2,218 individuals affected 437 with CL or CLP, and 4,537 unaffected relatives from 1,939 families that contain members 438 affected with CL and/or CLP. The types of OFCs present in a pedigree were obtained by direct 439 participation by affected individuals and/or by a reported family history of OFCs. An additional 440 2,673 unaffected individuals from 1,474 families with no reported history of an OFC (referred to 441 as Controls) are included in the association analysis. Participants from pedigrees containing 442 individuals affected with a cleft palate only (CP), or having a reported family history of CP were 443 excluded from this study.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

444

## 445 **Definition of subtypes**



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.09.20.21263645;](https://doi.org/10.1101/2021.09.20.21263645) this version posted September 23, 2021. The copyright holder for this

490 assigned an unknown affection status, thereby excluding these members from the corresponding 491 GWAS.

#### 492 **Genome wide association**

493 We have shown previously that the degree of OFC risk at certain susceptibility loci varies 494 with ancestry of the sample participants [22]. In order to control for this variance, we first 495 classified subjects into four different genetically defined ancestry groups using the principal 496 component analysis-based classification defined in a previous study using POFC subjects [12]. 497 For each of the eight GWAS phenotypic samples defined above and shown in Fig 1, we first 498 analyzed each ancestry group separately, then combined the association outcomes using meta-499 analysis. The four ancestry-based groups were: AFR (participants of African origin), ASIA 500 (participants of Asian origin), EUR (those of European white origin), and CSA (participants of 501 Central and Southern American origin). Table 3 shows the breakdown of the analysis sample by 502 ancestry, pedigree type, and affection status.

503 Individual GWASs were run using the mixed-model association program, GENESIS [25]. 504 GENESIS uses a genetic relationship matrix (GRM) estimated from the observed genotype data 505 to account for population structure and familial relatedness, therefore, it is not necessary to 506 correct for population admixture using ancestry PCs. The use of a GRM is necessary to account 507 for population admixture within our ancestry-based subsets, which, in turn is due to the varying 508 geographical origin of participants in each of these subsets (see Supplementary Table S2 for a 509 breakdown by recruitment site). The genetic relationship matrix also provides an estimate of the 510 polygenic variance component. Significance of association is based on the score test, comparing 511 the maximum likelihood of disease outcomes conditional on observed genotypes at each variant 512 to the maximum likelihood of the unconditional polygenic model. GENESIS reports approximate

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 513 effect sizes in the form of betas, i.e. the log-likelihood ratio of the conditional and unconditional
- 514 model) and standard error of the effect size. In this study, the effect allele is fixed across all
- 515 GWASs as the minor allele at each variant identified in the combined POFC sample.
- 516 Table 3. Counts of pedigrees and participants by GWAS, ancestry and affection status



## 517 Note: †Ped=number of pedigrees, Case=number of affected individuals, ††UFM=unaffected

518 family member related to a case;†††the CONTROL subset consists of individuals/families 519 with no known personal nor family history of OFCs, and are utilized in each GWAS – the 520 number of CONTROL subjects are listed in the Ctrl columns to complete counts of 521 unaffected GWAS subjects.

522

523 Ancestry-specific GWASs were then meta-analyzed for each of the eight GWAS phenotypes 524 using the inverse-variance method implemented in PLINK [26]. The reported odds ratios from 525 PLINK were converted to log-scale effect sizes, to conform to the GENESIS reported effects. 526 The 95% confidence intervals of betas were calculated under the assumption that the meta-

527 analysis p-values are distributed normally. All four ancestry-groups were meta-analyzed for the

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 $528$  CL<sub>ICL+1</sub> and CLP<sub>ICLP+1</sub> subtypes. There are no AFR pedigrees containing both CL and CLP

529 affected members, therefore, meta-analysis was conducted excluding the African samples (AFR)

530 for the five family-subtypes ( $CL_{[CL]}$ ,  $CL_{[CL+CLP]}$ ,  $CLP_{[CLP]}$ ,  $CLP_{[CL+CLP]}$  and  $CL/P_{[CL+CLP]}$ ).

531

## 532 **Variant selection**

533 Genotyped and imputed variants that passed quality control, and had minor allele frequencies 534 of 2% or more within their respective GWAS sample subsets were used to run association. The 535 observed minor allele frequencies of reported loci were checked against values obtained from the 536 gnomAD database [27] to guard against imputation inaccuracy.

537

## 538 **Identification of novel associations**

539 For each genome-wide meta-analysis, variants showing association p-values below 1.0E-06 540 were selected for further investigation, and grouped into association peaks measuring 1MB or 541 less. We then checked for overlap between our associations peaks with the 29 genomic regions 542 listed as harboring known OFC genes by Beaty et al. [28] as well as associated regions reported 543 by six recently published OFC GWAS studies. The six recent GWASs include (1) combined 544 meta-analysis of parent-offspring trio and case-control cohorts from the current Pitt-OFC 545 multiethnic study sample [12], (2) meta-analysis of the cohorts used in (1) with another OFC 546 sample consisting of European and Asian participants [13], (3) GWAS of cleft lip with cleft 547 palate in Han Chinese samples [18], (4) GWAS of cleft lip only and cleft palate only in Han 548 Chinese [19], (5) GWAS of cleft lip with or without cleft palate in Dutch and Belgian 549 participants [29] and (6) GWAS of sub-Saharan African participants from Nigeria, Ghana, 550 Ethiopia and the Republic of Congo [30].

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

551 For each OFC gene, we checked if any our 1 MB association peaks overlapped with the span

- 552 of the gene, as determined by its start and end transcription sites. The base pair positions for start
- 553 and end transcription sites were obtained from the UCSC genome browser

554 (https://genome.ucsc.edu/index.html) mapped to the February 2009 (GRCh37) assembly. For the

- 555 8q24.21 locus, which is a gene desert, we checked whether any of our associated SNPs were
- 556 located in the 8q24.21 chromosome band. The distance between variants published by the six
- 557 recent GWASs and our variants with p-values below 1.0E-06 were similarly measured, and a

558 positive overlap reported if this distance was less than 500 Kb.

559

## 560 **Comparison of association outcomes between subtypes**

561 Within each peak region the variant with the smallest meta-analysis association p-value 562 observed for each of the eight subtypes were selected and their effect sizes compared. Effect size 563 of each variant is represented by the beta coefficient of the SNP main effect under an additive 564 model of inheritance, setting the minor allele (based on the entire POFC study sample) as the 565 effect allele. Effect size and magnitude were compared across subtypes for the variants selected 566 for each subtype to determine whether the 95% confidence intervals of effect size estimates 567 overlapped. Next, LD r<sup>2</sup> between selected variants at each locus was calculated using the PLINK 568 program and the set of genotyped founders in the full POFC sample, irrespective of their OFC 569 status. Finally, the observed effect allele frequency (EAF) within cases from the two GWASs 570 were examined to assess whether these differed significant between cleft subtypes. We have 571 previously shown that ancestry impacts association to CL/P in our POFC sample [22]; therefore, 572 we examined the subtype-specific effect sizes within each ancestry group to assess whether the 573 differences observed were similar to the those observed for the meta-analysis. EAFs within cases It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

574 were also compared across the eight phenotypic subtypes within each ancestry group in addition 575 to the cases pooled across ancestry groups for each phenotypic subset. In our study, we did not 576 carry out a statistical test (e.g. Cochran's Q statistic) to compare association outcomes from the 577 OFC subtypes, as the unaffected relatives of OFC subjects and subjects from control families 578 were used in the GWAS of more than one subtype; therefore, we relied mainly on qualitative 579 evaluation of differences in the association outcomes.

## 580 **ACKNOWLEDGEMENTS**

581 The authors wish to thank the participant families worldwide, without whom this research 582 would not have been possible. Special thanks to Dr. Eduardo Castilla (deceases), Dr. Juan C. 583 Mereb, Dr. Andrew Czeizel, and to the devoted staff at the many recruitment sites. This work 584 was supported by grants from the National Institutes of Health including: X01-HG007485 585 [MLM], R01-DE016148 [MLM, SMW], U01-DE024425 [MLM], R37-DE008559 [JCM, 586 MLM], R01-DE009886 [MLM], R21-DE016930 [MLM], R01-DE014667 [LMM], R21- 587 DE016930 [MLM], R01-DE012472 [MLM], R01-DE011931 [JTH], U01-DD000295 [GLW], 588 R00-DE025060 [EJL], R01- DE028342 [EJL], R01- DE28300 [AB]. Genotyping and data 589 cleaning were provided via an NIH contract to the Johns Hopkins Center for Inherited Disease 590 Research: HHSN268201200008I. Additional support provided by: an intramural grant from the 591 Research Institute of the Children's Hospital of Colorado [FWD]; operating costs support in the 592 Philippines was provided by the Institute of Human Genetics, National Institutes of Health, 593 University of the Philippines, Manila [CP]; grants through FAPERJ [IMO].

## 594 **BIBLIOGRAPHY**

595 1. Nidey N, Moreno Uribe LM, Marazita MM, Wehby GL. Psychosocial well-being of 596 parents of children with oral clefts. Child: care, health and development. 2016;42(1):42-50.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.09.20.21263645;](https://doi.org/10.1101/2021.09.20.21263645) this version posted September 23, 2021. The copyright holder for this

597 2. Wehby GL, Cassell CH. The impact of orofacial clefts on quality of life and healthcare 598 use and costs. Oral diseases. 2010;16(1):3-10.

599 3. Berk NW, Marazita ML. The Costs of Cleft Lip and Palate: Personal and Societal

600 Implications. In: Wyszynski DF, editor. Cleft Lip and Palate: From Origin to Treatment. Oxford:

601 Oxford University Press; 2002.

602 4. Nidey N, Wehby G. Barriers to Health Care for Children with Orofacial Clefts: A

603 Systematic Literature Review and Recommendations for Research Priorities. Oral Health and

604 Dental Studies. 2019;2(1):2.

605 5. Naros A, Brocks A, Kluba S, Reinert S, Krimmel M. Health-related quality of life in cleft

606 lip and/or palate patients - A cross-sectional study from preschool age until adolescence. Journal

607 of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-

608 Maxillo-Facial Surgery. 2018;46(10):1758-63.

609 6. Bille C, Winther JF, Bautz A, Murray JC, Olsen J, Christensen K. Cancer risk in persons

610 with oral cleft--a population-based study of 8,093 cases. American journal of epidemiology.

611 2005;161(11):1047-55.

612 7. Bui AH, Ayub A, Ahmed MK, Taioli E, Taub PJ. Association Between Cleft Lip and/or

613 Cleft Palate and Family History of Cancer: A Case-Control Study. Annals of plastic surgery.

614 2018;80(4 Suppl 4):S178-s81.

615 8. Taioli E, Ragin C, Robertson L, Linkov F, Thurman NE, Vieira AR. Cleft lip and palate 616 in family members of cancer survivors. Cancer investigation. 2010;28(9):958-62.

617 9. Dixon MJ, Marazita ML, Beaty TH, Murray JC. Cleft lip and palate: understanding

618 genetic and environmental influences. Nature reviews Genetics. 2011;12(3):167-78.



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2021.09.20.21263645;](https://doi.org/10.1101/2021.09.20.21263645) this version posted September 23, 2021. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grant



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 663 25. Gogarten S, Sofer T, Chen H, Yu C, Brody J, Thornton T, et al. Genetic association
- 664 testing using the GENESIS R/Bioconductor package. Bioinformatics. 2019.
- 665 26. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- 666 PLINK: rising to the challenge of larger and richer datasets. GigaScience. 2015;4(1).
- 667 27. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. Variation
- 668 across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance
- 669 across human protein-coding genes. 2019:531210.
- 670 28. Beaty TH, Marazita ML, Leslie EJ. Genetic factors influencing risk to orofacial clefts:
- 671 today's challenges and tomorrow's opportunities. F1000Research. 2016;5:2800.
- 672 29. van Rooij IA, Ludwig KU, Welzenbach J, Ishorst N, Thonissen M, Galesloot TE, et al.
- 673 Non-Syndromic Cleft Lip with or without Cleft Palate: Genome-Wide Association Study in
- 674 Europeans Identifies a Suggestive Risk Locus at 16p12.1 and Supports SH3PXD2A as a Clefting
- 675 Susceptibility Gene. Genes. 2019;10(12).
- 676 30. Butali A, Mossey PA, Adeyemo WL, Eshete MA, Gowans LJJ, Busch TD, et al.
- 677 Genomic analyses in African populations identify novel risk loci for cleft palate. Human
- 678 molecular genetics. 2019;28(6):1038-51.













 $0.15$ 



